Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | SLC26A3 | P40879 | 2/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30010243 | 1.00 | MRGPRX4 (0.40) | MRGPRX4XDHSLC22A12KDM4EGLA | |
| SCHEMBL29634143 | 0.89 | SLC26A3 (0.35) | MRGPRX4SLC26A3NR1H2NR1H3 | |
| SCHEMBL21438449 | 0.89 | SLC26A3 (0.35) | MRGPRX4SLC26A3NR1H2NR1H3 | |
| SCHEMBL21437548 | 0.88 | MRGPRX4 (0.37) | MRGPRX4SLC26A3 | |
| SCHEMBL21437971 | 0.87 | MRGPRX4 (0.36) | MRGPRX4KDM4ESLC26A3 | |
| SCHEMBL23217616 | 0.87 | CFD (0.38) | SLC26A3 | |
| SCHEMBL30010617 | 0.87 | CFD (0.38) | SLC26A3 | |
| SCHEMBL21438698 | 0.86 | CFD (0.38) | MRGPRX4KDM4ESLC26A3NR1H2NR1H3 | |
| SCHEMBL21438098 | 0.83 | MRGPRX4 (0.39) | MRGPRX4SLC26A3 | |
| SCHEMBL31026075 | 0.83 | MRGPRX4 (0.39) | MRGPRX4SLC26A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-09-04 | — | — | US | disclosed |
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114555570-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | MRGPRX4 683/4885XDH 293/4885SLC22A12 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.